Search results
Results from the WOW.Com Content Network
AbbVie Inc's rheumatoid arthritis drug Humira and Roche Holding AG's cancer drug Rituxan topped a list of seven treatments whose combined 2017 and 2018 price hikes accounted for a $5.1 billion ...
Rituximab, sold under the brand name Rituxan among others, is a monoclonal antibody medication used to treat certain autoimmune diseases and types of cancer. [18] It is used for non-Hodgkin lymphoma, chronic lymphocytic leukemia (in children and adults, but not recommended in elderly patients), rheumatoid arthritis, granulomatosis with polyangiitis, idiopathic thrombocytopenic purpura ...
High drug prices can sometimes be a necessity to finance the high-risk and high-cost nature of pharmaceutical R&D. [93] 11% of drug candidates that enter clinical trials are successful and receive approval for sale. [94] Although the cost of manufacturing is relatively low, the cost of developing a new drug is relatively high.
Specialty drugs are now so expensive that they are leading to increases in insurance premiums. [58] Control of specialty drug prices will require research to identify effective policy options, which may include: decreasing regulation, limiting patent protection, allowing negotiation of drug prices by Medicare, or pricing drugs based on their ...
Amgen (AMGN) markets Mvasi and Kanjinti, biosimilar versions of Avastin and Herceptin, respectively in the United States, and Kanjinti and Amgevita, biosimilar of Humira, in the EU.
For premium support please call: 800-290-4726 more ways to reach us
Cancer immunotherapy (immuno-oncotherapy) is the stimulation of the immune system to treat cancer, improving the immune system's natural ability to fight the disease. [1] It is an application of the fundamental research of cancer immunology (immuno-oncology) and a growing subspecialty of oncology.
There are reports comparing these treatments in front of each other. Restricting the research only to relapses, it seems that alemtuzumab is the most cost effective [21] while anti-CD20 monoclonal antibodies (Rituxan, Ocrevus) have the better safety vs. efficacy profile [22]